Clinical Trial

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-22.
Trial Details
NCT Number NCT06950034
Lead Sponsor Solu Therapeutics, Inc
Conditions Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Refractory Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) +4 more
Enrollment 105 participants
Start Date 2025-03-13
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-09